Reed Elsevier share price: Publisher to flip subscription journals to open access

on Dec 18, 2013
Updated: Oct 21, 2019
Listen, Wednesday, December 18: Academic publisher Elsevier, part of Reed Elsevier Plc (LON:REL), is to convert seven subscription journals to open access from next year, the company has said.

In other company news, Elsevier last week announced that it had deployed a unified clinical medication platform in China.
Reed Elsevier’s share price has climbed about 0.3 percent in morning trading in London today. The stock is currently up a shade under 37 percent intra-year.
**Open-access journals**
The publisher, which concentrates on online subscriptions and research products, said in a statement yesterday that it would ‘flip’ seven journals from subscription-based to open access starting from January 1, 2014. Among the journals are Physics Letters B and Nuclear Physics B which Elsevier makes available as part of its participation in the Sponsoring Consortium for Open Access Publishing in Particle Physics (SCOAP3) initiative.

Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.

“This announcement is part of Elsevier’s ongoing effort to help facilitate further implementation of open access options”, Philippe Terheggen, Managing Director of STM journals at Elsevier, said in the statement.
The company noted that providing open access to the journals would not affect their editorial standards, with the publication costs to be covered by article processing fees paid by authors and, in the case of the physics journals, by the SCOAP3 consortium.

**China focus**
In other Elsevier news, the company said last Thursday that it had successfully deployed a unified clinical medication decision support solution at a hospital in the People’s Republic of China. The platform, known as Clinical Medication Decision Support All (CMDS-All), integrates medical and pharmacological applications in a single solution platform.

Yukun Harsono, Managing Director of Elsevier for Greater China, said in a statement: “Continuous reforms in China’s health care sector are requiring medical and health organisations to provide safer, faster and more efficient medical services with greater accuracy for better patient care, and CMDS-All is the one-stop clinical medication decision support system that addresses those needs.”

University World News reports that, in addition to the CMDS-All platform, Elsevier is considering the publication in China of English-language journals, in a venture with China Science Publishing & Media company.
The PRC is emerging as a major contributor to the international scientific community. “The joint venture puts Elsevier at the centre of services to burgeoning Chinese research and development,” Elsevier CEO Ron Mobed said, as quoted by University World News. “China is committing major resources in R&D and is in line to surpass the UK and US to become the world’s largest investor.”
**As of 08:19 UTC, buy Reed Elsevier shares at 867.50p.**
**As of 08:19 UTC, sell Reed Elsevier shares at 866.50p.**
Trade stocks with Hargreaves Lansdown from £5.95 per deal.
Prices can go up and down meaning you can get back less than you invest. This is not advice. Dealing services provided by Hargreaves Lansdown.


Want easy-to-follow crypto, forex & stock trading signals? Make trading simple by copying our team of pro-traders. Consistent results. Sign-up today at Invezz Signals.

Learn more
Media Stock Market